Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus POLARAMINE.
LIVOSTIN vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category C
Category C
Antihistamine
Antihistamine